Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Total Debt (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Total Debt for 7 consecutive years, with $7.7 million as the latest value for Q4 2025.

  • Quarterly Total Debt fell 8.33% to $7.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.7 million through Dec 2025, down 8.33% year-over-year, with the annual reading at $7.7 million for FY2025, 8.33% down from the prior year.
  • Total Debt for Q4 2025 was $7.7 million at Beam Therapeutics, up from $6.5 million in the prior quarter.
  • The five-year high for Total Debt was $85.4 million in Q2 2021, with the low at $3.9 million in Q2 2025.
  • Average Total Debt over 5 years is $22.1 million, with a median of $13.2 million recorded in 2023.
  • The sharpest move saw Total Debt surged 596.19% in 2021, then plummeted 80.8% in 2022.
  • Over 5 years, Total Debt stood at $42.2 million in 2021, then tumbled by 56.64% to $18.3 million in 2022, then tumbled by 40.98% to $10.8 million in 2023, then fell by 22.22% to $8.4 million in 2024, then dropped by 8.33% to $7.7 million in 2025.
  • According to Business Quant data, Total Debt over the past three periods came in at $7.7 million, $6.5 million, and $3.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.